Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ensifentrine in Healthy Chinese Subjects
NCT05758428Phase 1Completed
- Sponsor
- Nuance Pharma
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (2 cohorts), sponsored by Nuance Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 2 more. Started Mar 2023; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05758428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758428.